European Journal of Dermatology 2019/6 Vol. 29
Journal article

Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma

Pages 636 to 640

Cite this article

  • LAVAUD, Justine,
  • BLOM, Astrid,
  • LONGVERT, Christine,
  • FORT, Magali,
  • FUNCK-BRENTANO, Elisa
  • and SAIAG, Philippe,
2019. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma. European Journal of Dermatology, 2019/6 Vol. 29, p.636-640. DOI : 10.1684/ejd.2019.3671. URL : https://stm.cairn.info/revue-european-journal-of-dermatology-2019-6-page-636?lang=en.
  • Lavaud, Justine.,
  • et al.
« Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma ». European Journal of Dermatology, 2019/6 Vol. 29, 2019. p.636-640. CAIRN.INFO, stm.cairn.info/revue-european-journal-of-dermatology-2019-6-page-636?lang=en.
  • Lavaud, J.,
  • Blom, A.,
  • Longvert, C.,
  • Fort, M.,
  • Funck-Brentano, E.
  • and Saiag, P.
(2019). Pembrolizumab and Concurrent Hypo-Fractionated Radiotherapy for Advanced Non-Resectable Cutaneous Squamous Cell Carcinoma. European Journal of Dermatology, . 29(6), 636-640. https://doi.org/10.1684/ejd.2019.3671.

https://doi.org/10.1684/ejd.2019.3671

Full-text article
Abstract
Bibliography
Authors
Figures
  • [1] Que S.K.T., Zwald F.O., Schmults C.D. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78:249-261.
  • [2] Foote M.C., McGrath M., Guminski A. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25:2047-2052.
  • [3] Schadendorf D., van Akkooi A., Berking C. Melanoma. Lancet. 2018;392:971-984.
  • [4] https: //www.ema.europa.eu/en/medicines/human/EPAR/keytruda#authorisation-details-section. Accessed 01 March 2019.
  • [5] Pickering C.R., Zhou J.H., Lee J.J. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20:6582-6592.
  • [6] Belai E.B., de Oliveira C.E., Gasparoto T.H. PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis. 2014;35:424-431.
  • [7] Blum V., Müller B., Hofer S. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. Eur J Dermatol. 2018;28:78-81.
  • [8] Deinlein T., Lax S.F., Schwarz T., Giuffrida R., Schmid-Zalaudek K., Zalaudek I. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature. Eur J Cancer. 2017;83:99-102.
  • [9] Assam J.H., Powell S., Spanos W.C. Unresectable cutaneous squamous cell carcinoma of the forehead with mutation showing dramatic response to programmed cell death protein 1 inhibitor therapy. Clin Skin Cancer. 2016;1:26-29. MLH1
  • [10] Borradori L., Sutton B., Shayesteh P., Daniels G.A. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016;175:1382-1386.
  • [11] Chang A.L.S., Kim J., Luciano R., Sullivan-Chang L., Colevas A.D. A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatol. 2016;152:106-108.
  • [12] Ravulapati S., Leung C., Poddar N., Tu Y. Immunotherapy in squamous cell skin carcinoma: a game changer? Am J Med. 2017;130:e207-e208.
  • [13] Degache E., Crochet J., Simon N. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2018;32:e257-e258.
  • [14] Miller D.M., Faulkner-Jones B.E., Stone J.R., Drews R.E. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Rep. 2017;3:412-415.
  • [15] Winkler J.K., Schneiderbauer R., Bender C. Anti-programmed cell death-1 therapy in non-melanoma skin cancer. Br J Dermatol. 2017;176:498-502.
  • [16] Chen A., Ali N., Boasberg P., Ho A.S. Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab. J Clin Med. 2018;7:1.
  • [17] Stevenson M.L., Wang C.Q.F., Abikhair M. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153:299-303.
  • [18] De Wolf K., Kruse V., Sundahl N. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. J Transl Med. 2017;15:21.
  • [19] Migden M.R., Rischin D., Schmults C.D. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341-351.
  • [20] Roger A., Finet A., Boru B. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. Oncoimmunology. 2018;7:e1442166.
  • [21] World Medical Association Declaration of Helsinki:. ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194.
  • [22] Sharabi A.B., Nirschl C.J., Kochel C.M. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3:345-355.
  • [23] Rodriguez-Ruiz M.E., Vanpouille-Box C., Melero I., Formenti S.C., Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39:644-655.